Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Oligonucleotide Therapeutics Market Size, Share, and Trends Report, 2026-2033 | ASO, siRNA, and Delivery Innovation Drive 19.4% CAGR Toward a USD 29.6 Billion Market by 2033

globenewswire.com
IONS Ionis Pharmaceuticals is listed as a key player in the growing oligonucleotide therapeutics market, which is projected to reach $29.6 billion by 2033 with a 19.4% CAGR. The company benefits from advancements in RNA-based medicines and precision medicine. ALNY Alnylam Pharmaceuticals is identified as a key participant in the expanding oligonucleotide therapeutics market, driven by innovation in ASO, siRNA, and delivery technologies. The market is expected to grow significantly, benefiting companies like Alnylam. SRPT Sarepta Therapeutics is recognized as a significant company in the oligonucleotide therapeutics market, which is experiencing robust growth driven by RNA-based medicines and precision medicine advancements. The market forecast indicates substantial expansion. BIIB Biogen is mentioned as a company involved in the oligonucleotide therapeutics market, which is poised for significant growth. The article highlights advancements in RNA-targeting technologies and precision medicine, areas where Biogen participates. NVS Novartis is listed as a participant in the oligonucleotide therapeutics market, which is projected to grow substantially. The company benefits from the overall market expansion driven by RNA-based medicines and precision medicine advancements. ROG Roche is identified as a company within the expanding oligonucleotide therapeutics market. The article forecasts significant market growth driven by technological innovations and increasing demand for precision medicine. ARWR Arrowhead Pharmaceuticals is highlighted as a key player in the rapidly growing oligonucleotide therapeutics market. The company is well-positioned to benefit from advancements in siRNA technology and the overall market expansion. WVE Wave Life Sciences is mentioned as a company in the oligonucleotide therapeutics space, which is experiencing strong growth. The market's expansion, driven by RNA-based medicines and delivery innovations, is positive for companies like Wave. SLN Silence Therapeutics is listed as a participant in the oligonucleotide therapeutics market, which is projected for substantial growth. The company benefits from advancements in RNA-targeting technologies and the overall market expansion.

Oligonucleotide Therapeutics Market Size, Share, and Trends Report, 2026-2033 | ASO, siRNA, and Delivery Innovation Drive 19.4% CAGR Toward a USD 29.6 Billion Market by 2033 Dublin, Oct. 29, 2026 (GLOBE NEWSWIRE) -- "Oligonucleotide Therapeutics Market Size, Share & Trends Analysis Report by Oligonucleotide Class, Therapeutic Area, Route of Administration, Region, and Segment Forecasts, 2026-2033" has been added to ResearchAndMarkets.com's offering.

The global oligonucleotide therapeutics market was valued at an estimated USD 7.20 billion in 2025 and is projected to reach USD 29.60 billion by 2033. The market is expected to expand at a compound annual growth rate of 19.40% from 2026 to 2033, supported by increasing investment in RNA-based medicines and precision medicine.

Pharmaceutical and biotechnology companies are advancing oligonucleotide therapeutics for rare genetic disorders, oncology, neurological diseases, cardiometabolic conditions, infectious diseases, and other chronic illnesses. Progress in antisense oligonucleotides, small interfering RNA therapeutics, microRNA platforms, aptamers, and other RNA-targeting technologies is broadening the clinical potential of gene-modulating medicines across multiple therapeutic areas.

Innovation in drug delivery remains a significant growth driver for the global oligonucleotide therapeutics market. Technologies such as lipid nanoparticles and GalNAc conjugates are improving drug stability, tissue-specific targeting, cellular uptake, and therapeutic performance. These developments are helping address delivery challenges that have historically limited the clinical application of nucleic acid therapeutics.

The market is also benefiting from increasing regulatory approvals, expanding clinical pipelines, and the commercialization of RNA-based therapies. These factors are strengthening confidence among pharmaceutical companies, biotechnology developers, healthcare stakeholders, and investors. Growing demand for targeted treatments is further encouraging the development of next-generation oligonucleotide therapeutics with improved efficacy, safety, and dosing profiles.

Artificial intelligence, automation, and computational biology are becoming increasingly important across oligonucleotide drug discovery and development. Companies are adopting digital platforms to enhance target identification, optimize oligonucleotide design, evaluate potential candidates, and shorten preclinical development timelines. The integration of advanced analytics is supporting more efficient, data-driven research models while helping developers prioritize promising therapeutic targets.

Strategic collaborations between RNA-focused biotechnology companies, established pharmaceutical manufacturers, academic institutions, and technology-driven drug discovery firms are also shaping the competitive landscape. These partnerships provide access to specialized delivery systems, computational capabilities, research expertise, and commercialization resources. As competition intensifies within precision medicine, market participants are pursuing innovation-focused alliances, licensing agreements, and platform expansion strategies to strengthen their RNA therapeutic pipelines.

Market Segmentation

The report analyzes revenue growth at global, regional, and country levels and evaluates industry trends across key market segments from 2021 to 2033. The analysis covers oligonucleotide class, therapeutic area, route of administration, and region.

Oligonucleotide Class Outlook (Revenue, USD Million, 2021-2033)

Therapeutic Area Outlook (Revenue, USD Million, 2021-2033)

Route of Administration Outlook (Revenue, USD Million, 2021-2033)

Regional Outlook (Revenue, USD Million, 2021-2033)

Continued advances in RNA-targeting platforms, delivery technologies, digital drug discovery, and strategic partnerships are expected to support sustained market growth through 2033. Expanding clinical validation and broader commercial adoption will further position oligonucleotide therapeutics as an important segment of precision medicine and pharmaceutical innovation.

Key Attributes:

Key Topics Covered:

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope

1.2. Segment Definitions

1.2.1. Oligonucleotide Class

1.2.2. Therapeutic Area

1.2.3. Route of Administration

1.3. Estimates and Forecast Timeline

1.4. Research Methodology

1.5. Information Procurement

1.5.1. Purchased Database

1.5.2. Internal Database

1.5.3. Secondary Sources

1.5.4. Primary Research

1.6. Information Analysis

1.6.1. Data Analysis Models

1.7. Market Formulation & Data Visualization

1.8. Model Details

1.8.1. Commodity Flow Analysis

1.9. List of Secondary Sources

1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Snapshot

2.2. Segment Snapshot

2.3. Competitive Landscape Snapshot

Chapter 3. Oligonucleotide Therapeutics Market Variables, Trends, & Scope

3.1. Market Lineage Outlook

3.2. Market Dynamics

3.2.1. Market Driver Analysis

3.2.2. Market Restraint Analysis

3.3. Business Environment Analysis

3.3.1. Industry Analysis - Porter's Five Forces Analysis

3.3.1.1. Supplier Power

3.3.1.2. Buyer Power

3.3.1.3. Substitution Threat

3.3.1.4. Threat of New Entrants

3.3.1.5. Competitive Rivalry

3.3.2. PESTLE Analysis

Chapter 4. Oligonucleotide Therapeutics Market: Oligonucleotide Class Business Analysis

4.1. Oligonucleotide Class Market Share, 2025 & 2033

4.2. Oligonucleotide Class Segment Dashboard

4.3. Market Size & Forecasts and Trend Analysis, by Oligonucleotide Class, 2021 to 2033 (USD Million)

4.4. Antisense Oligonucleotides (ASOs)

4.4.1. Antisense Oligonucleotides (ASOs) Market, 2021 - 2033 (USD Million)

4.5. Small Interfering RNA (siRNA)

4.5.1. Small Interfering RNA (siRNA) Market, 2021 - 2033 (USD Million)

4.6. Aptamers

4.6.1. Aptamers Market, 2021 - 2033 (USD Million)

4.7. microRNA (miRNA)

4.7.1. microRNA (miRNA) Market, 2021 - 2033 (USD Million)

4.8. CpG Oligonucleotides

4.8.1. CpG Oligonucleotides Market, 2021 - 2033 (USD Million)

4.9. Other

4.9.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Oligonucleotide Therapeutics Market: Therapeutic Area Business Analysis

5.1. Therapeutic Area Market Share, 2025 & 2033

5.2. Therapeutic Area Segment Dashboard

5.3. Market Size & Forecasts and Trend Analysis, by Therapeutic Area, 2021 to 2033 (USD Million)

5.4. Neurology

5.4.1. Neurology Market, 2021 - 2033 (USD Million)

5.5. Oncology

5.5.1. Oncology Market, 2021 - 2033 (USD Million)

5.6. Cardiometabolic Disorders

5.6.1. Cardiometabolic Disorders Market, 2021 - 2033 (USD Million)

5.7. Infectious Diseases

5.7.1. Infectious Diseases Market, 2021 - 2033 (USD Million)

5.8. Ophthalmology

5.8.1. Ophthalmology Market, 2021 - 2033 (USD Million)

5.9. Others

5.9.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Oligonucleotide Therapeutics Market: Route of Administration Business Analysis

6.1. Route of Administration Market Share, 2025 & 2033

6.2. Route of Administration Segment Dashboard

6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Million)

6.4. Subcutaneous

6.4.1. Subcutaneous Market, 2021 - 2033 (USD Million)

6.5. Intravenous

6.5.1. Intravenous Market, 2021 - 2033 (USD Million)

6.6. Intrathecal

6.6.1. Intrathecal Market, 2021 - 2033 (USD Million)

6.7. Intramuscular

6.7.1. Intramuscular Market, 2021 - 2033 (USD Million)

6.8. Others

6.8.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. Oligonucleotide Therapeutics Market: Regional Estimates & Trend Analysis

7.1. Regional Market Share Analysis, 2025 & 2033

7.2. Regional Market Dashboard

7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033

7.3.1. Country Analysis Framework

7.3.1.1. Key Country Dynamics

7.3.1.2. Target Disease Prevalence

7.3.1.3. Regulatory Framework

7.3.1.4. Reimbursement Framework

7.4. North America

7.4.1. North America Oligonucleotide Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)

7.4.2. U.S. Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

7.4.3. Canada Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

7.4.4. Mexico Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

7.5. Europe

7.5.1. Europe Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

7.5.2. UK Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

7.5.3. Germany Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

7.5.4. France Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

7.5.5. Italy Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

7.5.6. Spain Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

7.5.7. Denmark Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

7.5.8. Sweden Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

7.5.9. Norway Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

7.6. Asia Pacific

7.6.1. Asia Pacific Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

7.6.2. Japan Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

7.6.3. China Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

7.6.4. India Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

7.6.5. Australia Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

7.6.6. South Korea Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

7.6.7. Thailand Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

7.7. Latin America

7.7.1. Latin America Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

7.7.2. Brazil Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

7.7.3. Argentina Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

7.8. Middle East and Africa

7.8.1. Middle East and Africa Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

7.8.2. South Africa Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

7.8.3. Saudi Arabia Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

7.8.4. UAE Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

7.8.5. Kuwait Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

8.1. Participant Overview

8.2. Company Market Position Analysis

8.3. Company Categorization

8.4. Strategy Mapping

8.5. Company Profiles/Listing

8.5.1. Company Profile Framework

8.5.1.1. Overview

8.5.1.2. Financial Performance

8.5.1.3. Product Benchmarking

8.5.1.4. Strategic Initiatives

8.5.2. Ionis Pharmaceuticals

8.5.3. Alnylam Pharmaceuticals

8.5.4. Sarepta Therapeutics

8.5.5. Biogen

8.5.6. Novartis

8.5.7. Roche

8.5.8. Arrowhead Pharmaceuticals

8.5.9. Wave Life Sciences

8.5.10. Silence Therapeutics

8.5.11. Nitto Denko Avecia

List of Tables [95]

List of Figures [88]

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/ylc3zd

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.